181 related articles for article (PubMed ID: 22761471)
1. Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors.
Wildeman MA; Novalic Z; Verkuijlen SA; Juwana H; Huitema AD; Tan IB; Middeldorp JM; de Boer JP; Greijer AE
Clin Cancer Res; 2012 Sep; 18(18):5061-70. PubMed ID: 22761471
[TBL] [Abstract][Full Text] [Related]
2. Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.
Novalić Z; Verkuijlen SAWM; Verlaan M; Eersels JLH; de Greeuw I; Molthoff CFM; Middeldorp JM; Greijer AE
J Med Virol; 2017 Dec; 89(12):2207-2216. PubMed ID: 28853217
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.
Stoker SD; Novalić Z; Wildeman MA; Huitema AD; Verkuijlen SA; Juwana H; Greijer AE; Tan IB; Middeldorp JM; de Boer JP
J Cancer Res Clin Oncol; 2015 Oct; 141(10):1845-57. PubMed ID: 25920375
[TBL] [Abstract][Full Text] [Related]
4. Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma.
Hsu CL; Kuo YC; Huang Y; Huang YC; Lui KW; Chang KP; Lin TL; Fan HC; Lin AC; Hsieh CH; Lee LY; Wang HM; Li HP; Chang YS
Oncotarget; 2015 Oct; 6(31):31323-34. PubMed ID: 26416517
[TBL] [Abstract][Full Text] [Related]
5. Curcuminoids as EBV Lytic Activators for Adjuvant Treatment in EBV-Positive Carcinomas.
Ramayanti O; Brinkkemper M; Verkuijlen SAWM; Ritmaleni L; Go ML; Middeldorp JM
Cancers (Basel); 2018 Mar; 10(4):. PubMed ID: 29565326
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation.
Lee HG; Kim H; Kim EJ; Park PG; Dong SM; Choi TH; Kim H; Chong CR; Liu JO; Chen J; Ambinder RF; Hayward SD; Park JH; Lee JM
Oncotarget; 2015 Oct; 6(31):31018-29. PubMed ID: 26427042
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir.
Hui KF; Cheung AK; Choi CK; Yeung PL; Middeldorp JM; Lung ML; Tsao SW; Chiang AK
Int J Cancer; 2016 Jan; 138(1):125-36. PubMed ID: 26205347
[TBL] [Abstract][Full Text] [Related]
8. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
Feng WH; Hong G; Delecluse HJ; Kenney SC
J Virol; 2004 Feb; 78(4):1893-902. PubMed ID: 14747554
[TBL] [Abstract][Full Text] [Related]
9. Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma.
Hui KF; Ho DN; Tsang CM; Middeldorp JM; Tsao GS; Chiang AK
Int J Cancer; 2012 Oct; 131(8):1930-40. PubMed ID: 22261816
[TBL] [Abstract][Full Text] [Related]
10. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation.
Xu FH; Xiong D; Xu YF; Cao SM; Xue WQ; Qin HD; Liu WS; Cao JY; Zhang Y; Feng QS; Chen LZ; Li MZ; Liu ZW; Liu Q; Hong MH; Shugart YY; Zeng YX; Zeng MS; Jia WH
J Natl Cancer Inst; 2012 Sep; 104(18):1396-410. PubMed ID: 22972969
[TBL] [Abstract][Full Text] [Related]
11. Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy.
Hu J; Li Y; Li H; Shi F; Xie L; Zhao L; Tang M; Luo X; Jia W; Fan J; Zhou J; Gao Q; Qiu S; Wu W; Zhang X; Liao W; Bode AM; Cao Y
Theranostics; 2020; 10(26):11921-11937. PubMed ID: 33204320
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Epstein-Barr virus reactivation in nasopharyngeal carcinoma cells by dietary sulforaphane.
Wu CC; Chuang HY; Lin CY; Chen YJ; Tsai WH; Fang CY; Huang SY; Chuang FY; Lin SF; Chang Y; Chen JY
Mol Carcinog; 2013 Dec; 52(12):946-58. PubMed ID: 22641235
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostics of nasopharyngeal carcinoma with Epstein-Barr virus (Herpesviridae, Lymphocryptovirus, HHV-4) serological and molecular markers in cases of undetected primary tumor location.].
Senyuta NB; Smirnova KV; Kondratova VN; Ignatova AV; Mudunov AM; Dushenkina TE; Liechtenstein AV; Gurtsevich VE
Vopr Virusol; 2019; 64(5):229-237. PubMed ID: 32167688
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of plasma Epstein-Barr virus DNA load to distinguish nasopharyngeal carcinoma patients from healthy high-risk populations in Southern China.
Ji MF; Huang QH; Yu X; Liu Z; Li X; Zhang LF; Wang P; Xie SH; Rao HL; Fang F; Guo X; Liu Q; Hong MH; Ye W; Zeng YX; Cao SM
Cancer; 2014 May; 120(9):1353-60. PubMed ID: 24477877
[TBL] [Abstract][Full Text] [Related]
15. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
[TBL] [Abstract][Full Text] [Related]
16. The synergistic effect of chemical carcinogens enhances Epstein-Barr virus reactivation and tumor progression of nasopharyngeal carcinoma cells.
Fang CY; Huang SY; Wu CC; Hsu HY; Chou SP; Tsai CH; Chang Y; Takada K; Chen JY
PLoS One; 2012; 7(9):e44810. PubMed ID: 23024765
[TBL] [Abstract][Full Text] [Related]
17. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
Zheng XH; Lu LX; Li XZ; Jia WH
Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
[TBL] [Abstract][Full Text] [Related]
18. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus mRNA profiles and viral DNA methylation status in nasopharyngeal brushings from nasopharyngeal carcinoma patients reflect tumor origin.
Ramayanti O; Juwana H; Verkuijlen SA; Adham M; Pegtel MD; Greijer AE; Middeldorp JM
Int J Cancer; 2017 Jan; 140(1):149-162. PubMed ID: 27600027
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib and SAHA synergistically induce ROS-driven caspase-dependent apoptosis of nasopharyngeal carcinoma and block replication of Epstein-Barr virus.
Hui KF; Lam BH; Ho DN; Tsao SW; Chiang AK
Mol Cancer Ther; 2013 May; 12(5):747-58. PubMed ID: 23475956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
